Furiex Pharmaceuticals is currently recruiting volunteers “to evaluate the effectiveness, safety, and tolerability of JNJ-27018966 (the Investigational drug) compared with an inactive placebo in patients with irritable bowel syndrome (IBS) with the subtype of diarrhea.” The study is open to “Eligible male and female patients aged 18 to 80 years with a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea.” For further information, call 1-877-345-2145.
This appears to be two simultaneous Phase III trials of the medication also known as MuDelta. The study listings on Clinical Trials.gov, linked above, currently show over 170 study sites throughout the United States, and the contact number above is a U.S. toll-free number. However, the Furiex press release, also linked here, indicates that study sites in Canada and the United Kingdom will also be available at an unspecified time. Please see the Clinical Trials.gov listings for specific U.S. sites and additional eligibility criteria, or contact Furiex directly.
Previous posts on open clinical trials for IBS can be found by clicking the clinical trials category in the blog archives on the upper right sidebar of this blog. We also have a page for IBS studies on the main IBS Impact site.The research and links pages and the July 26, 2011 post provide additional general resources.
We welcome researchers affiliated with academic, medical or pharmaceutical entities, or reputable organizations representing IBS or related or commonly overlapping conditions, to contact us directly with additional studies they wish to be considered for posting. Contact links for the founder/listowner and the webmaster can be found on the home page of the main IBS Impact website.
IBS Impact makes these study announcements available for general information, and encourages its members and site visitors to make their own individual, informed choices about their potential participation in any study. IBS Impact, as an entity, is not directly affiliated with any research sponsor and receives no funding from any source for studies or links we feature on this blog, the main site or social media.